Abstract
People are more likely to interact with other people of their ethnicity—a phenomenon known as ethnic homophily. In the United States, people of color are known to hold proportionately more high-contact jobs and are thus more at risk of virus infection. At the same time, these ethnic groups are on average younger than the rest of the population. This gives rise to interesting disease dynamics and non-trivial trade-offs that should be taken into consideration when developing prioritization strategies for future mass vaccine roll-outs.
Here, we study the spread of COVID-19 through the U.S. population, stratified by age, ethnicity, and occupation, using a detailed, previously-developed compartmental disease model. Based on historic data from the U.S. mass COVID-19 vaccine roll-out that began in December 2020, we show, (i) how ethnic homophily affects the choice of optimal vaccine allocation strategy, (ii) that, notwithstanding potential ethical concerns, differentiating by ethnicity in these strategies can improve outcomes (e.g., fewer deaths), and (iii) that the most likely social context in the United States is very different from the standard assumptions made by models which do not account for ethnicity and this difference affects which allocation strategy is optimal.
Highlights
A social mixing model accounting for ethnic homophily and variable job-related risk level is developed.
A scenario that differs strongly from standard homogeneous mixing assumptions best matches U.S. ethnicity-specific death and case counts.
Two trade-offs are explored: Should (i) old or young, and (ii) people of color or White and Asian people first receive COVID-19 vaccines?
Exhaustive simulation of a compartmental disease model identifies the optimal allocation strategy for different demographic groups.
Optimal strategies depend on the underlying mixing pattern and strategies that differentiate vaccine access by ethnicity outperform others.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript, all relevant code is available at GitHub: https://github.com/ckadelka/Ethnicity-and-vaccine-prioritization.
https://github.com/ckadelka/Ethnicity-and-vaccine-prioritization
